Thursday, July 10, 2008: 8:15 AM
Miami 3 (Gaylord Palms Resort & Convention Center)
Autism Spectrum Disorders are complex and multileveled. Partial insights can be gained at many levels but real understanding and constructive impact will be greater when investigators and care-givers integrate approaches across the many levels that are impacted in this set of conditions. In this CME course speakers will cover advances in our understandings at these multiple levels, and then, together with the audience, will dialog about how to bring these levels together into a comprehensive approach that can maximally improve options and quality of life in autism.
8:15am - 10:00 - Keynote Speaker (with rest of conference attendees) - Dr. Bob
Hendren (Sun Ballroom)
Break and Reconvene in CME track meeting space
10:30 - 11:15 - Dr. Martha Herbert, Harvard/MassGeneral
Introduction to a Whole Body System Approach to Autism
11:15 - 12:00 - Dr. Frank Sharp - M.I.N.D. Institute Gene Expression Changes in Children with AutismThis presentation will explain how RNA expression in peripheral blood can be used to study the genetic effects of a disease and environmental factors that affect neurological and psychiatric diseases. The possible changes of RNA expression in the blood of children with autism compared to control children will be shown.Break for Lunch1:00 - 1:45 - Doreen Granpeesheh, CARDTreating the Whole Child: An Integration of Biomedical and Behavioral Interventions Treatment approaches grounded in Applied Behavioral Analysis (ABA) are now considered to be at the forefront of educational interventions for children with autism. However, research supports a biomedical etiology for autism and while studies are conducted to identify exact biomedical pathways, many case studies point to successful outcome with biomedical treatments. While ABA and Biomedical practitioners have individually helped provide successful treatment models for autism, in developing a “Best Practices” Model, these interventions must work together to provide the best possibilities for successful outcome. Case studies will be presented in support of the behavioral-biomedical treatment model and recent research will be presented to show successful outcomes with these protocols. 1:45 - 2:30 - Dr. Amy Wetherby, Florida State UniversityBehavioral Markers of ASD Early in the Second Year: Implications for Early Intervention 2:30 - 3:15 - Dr. Emmanuelle Tognoli, Florida Atlantic University (in collaboration with Dr. Scott Kelso, FAU)Neuromarkers of social behavior: paving the way to electrophysiological endophenotypes of autismBREAK3:30 - 4:15 - Dr. Ken BockClinical Approaches to Detoxification in Children with Autism Spectrum DisordersIt is believed that environmental triggers, specifically toxicant exposures, coupled with genetic vulnerabilities have contributed to the dramatic increasing incidence of ASD in the past 2+ decades. Specifically, an impaired ability to detoxify these increasing toxic exposures may be particularly important. On a clinical level, approaches to enhanced detoxification have appeared to contribute to improvements in many children with autism spectrum disorder and will be discussed in this lecture. 4:15 - 5:00 - Panel discussion with all speakers (Frank Sharp has to leavebefore this)
Hendren (Sun Ballroom)
Break and Reconvene in CME track meeting space
10:30 - 11:15 - Dr. Martha Herbert, Harvard/MassGeneral
Introduction to a Whole Body System Approach to Autism
11:15 - 12:00 - Dr. Frank Sharp - M.I.N.D. Institute Gene Expression Changes in Children with AutismThis presentation will explain how RNA expression in peripheral blood can be used to study the genetic effects of a disease and environmental factors that affect neurological and psychiatric diseases. The possible changes of RNA expression in the blood of children with autism compared to control children will be shown.Break for Lunch1:00 - 1:45 - Doreen Granpeesheh, CARDTreating the Whole Child: An Integration of Biomedical and Behavioral Interventions Treatment approaches grounded in Applied Behavioral Analysis (ABA) are now considered to be at the forefront of educational interventions for children with autism. However, research supports a biomedical etiology for autism and while studies are conducted to identify exact biomedical pathways, many case studies point to successful outcome with biomedical treatments. While ABA and Biomedical practitioners have individually helped provide successful treatment models for autism, in developing a “Best Practices” Model, these interventions must work together to provide the best possibilities for successful outcome. Case studies will be presented in support of the behavioral-biomedical treatment model and recent research will be presented to show successful outcomes with these protocols. 1:45 - 2:30 - Dr. Amy Wetherby, Florida State UniversityBehavioral Markers of ASD Early in the Second Year: Implications for Early Intervention 2:30 - 3:15 - Dr. Emmanuelle Tognoli, Florida Atlantic University (in collaboration with Dr. Scott Kelso, FAU)Neuromarkers of social behavior: paving the way to electrophysiological endophenotypes of autismBREAK3:30 - 4:15 - Dr. Ken BockClinical Approaches to Detoxification in Children with Autism Spectrum DisordersIt is believed that environmental triggers, specifically toxicant exposures, coupled with genetic vulnerabilities have contributed to the dramatic increasing incidence of ASD in the past 2+ decades. Specifically, an impaired ability to detoxify these increasing toxic exposures may be particularly important. On a clinical level, approaches to enhanced detoxification have appeared to contribute to improvements in many children with autism spectrum disorder and will be discussed in this lecture. 4:15 - 5:00 - Panel discussion with all speakers (Frank Sharp has to leavebefore this)
Presenters:
Martha R. Herbert, Ph.D., M.D., Frank Sharp, M.D., Doreen Granpeesheh, Ph.D., BCBA, Amy Wetherby, Ph.D., CCC-SLP, Emmanuelle Tognoli, Kenneth A. Bock, M.D., FAAFP, FACN, CNS and Tim Buie, M.D.
See more of: General Submissions